Q3 EPS Estimate for Mirum Pharmaceuticals Reduced by Analyst

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – HC Wainwright decreased their Q3 2025 earnings per share estimates for shares of Mirum Pharmaceuticals in a report released on Wednesday, November 13th. HC Wainwright analyst E. Arce now expects that the company will post earnings per share of $0.35 for the quarter, down from their previous estimate of $0.46. HC Wainwright has a “Buy” rating and a $66.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.84) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2025 earnings at $0.61 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 40.98% and a negative net margin of 31.69%. The company’s revenue was up 89.4% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.57) EPS.

MIRM has been the subject of a number of other reports. Evercore ISI upped their target price on shares of Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. Cantor Fitzgerald upped their price objective on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 8th. Leerink Partners boosted their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Citigroup raised their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Robert W. Baird boosted their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Wednesday. Ten research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $57.73.

Mirum Pharmaceuticals Trading Up 5.3 %

Shares of NASDAQ:MIRM opened at $46.26 on Thursday. Mirum Pharmaceuticals has a 52-week low of $23.14 and a 52-week high of $48.89. The stock has a market capitalization of $2.21 billion, a price-to-earnings ratio of -23.55 and a beta of 1.16. The company has a debt-to-equity ratio of 1.34, a quick ratio of 3.09 and a current ratio of 3.28. The stock’s 50-day simple moving average is $39.96 and its two-hundred day simple moving average is $35.79.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its stake in Mirum Pharmaceuticals by 37.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock worth $40,131,000 after acquiring an additional 432,824 shares during the last quarter. Silvercrest Asset Management Group LLC increased its position in Mirum Pharmaceuticals by 64.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 162,817 shares of the company’s stock worth $4,090,000 after purchasing an additional 63,871 shares during the last quarter. Rice Hall James & Associates LLC raised its stake in Mirum Pharmaceuticals by 6.9% during the second quarter. Rice Hall James & Associates LLC now owns 229,730 shares of the company’s stock valued at $7,854,000 after purchasing an additional 14,843 shares in the last quarter. Candriam S.C.A. bought a new position in Mirum Pharmaceuticals during the second quarter valued at $17,384,000. Finally, Hennion & Walsh Asset Management Inc. grew its stake in shares of Mirum Pharmaceuticals by 64.9% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 104,770 shares of the company’s stock worth $3,582,000 after buying an additional 41,236 shares in the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.